“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

On Wednesday, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) ...

A Dutch court ruled on Wednesday that billionaire and global vaccine proponent, Bill Gates, must stand trial in the ...

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.